.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Fuji
Merck
Moodys
Baxter
Queensland Health
Federal Trade Commission
Dow
Citi

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091072

« Back to Dashboard
NDA 091072 describes RIVASTIGMINE TARTRATE, which is a drug marketed by Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, Alembic Pharms Ltd, and Ajanta Pharma Ltd, and is included in ten NDAs. It is available from seventeen suppliers. Additional details are available on the RIVASTIGMINE TARTRATE profile page.

The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.

Summary for 091072

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 091072

Mechanism of ActionCholinesterase Inhibitors

Suppliers and Packaging for NDA: 091072

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL 091072 ANDA Golden State Medical Supply, Inc. 60429-393 60429-393-60 60 CAPSULE in 1 BOTTLE (60429-393-60)
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL 091072 ANDA Golden State Medical Supply, Inc. 60429-394 60429-394-60 60 CAPSULE in 1 BOTTLE (60429-394-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:May 16, 2013TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 3MG BASE
Approval Date:May 16, 2013TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 4.5MG BASE
Approval Date:May 16, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
UBS
QuintilesIMS
Farmers Insurance
US Department of Justice
Federal Trade Commission
Cantor Fitzgerald
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot